Hucog HP: High-Purity hCG for Precision Hormone Therapy
Hucog HP
| Product dosage: 10000iu | |||
|---|---|---|---|
| Package (num) | Per injection | Price | Buy |
| 1 | $70.00 | $70.00 (0%) | 🛒 Add to cart |
| 2 | $67.00 | $140.00 $134.00 (4%) | 🛒 Add to cart |
| 3 | $65.00 | $210.00 $195.00 (7%) | 🛒 Add to cart |
| 4 | $63.00 | $280.00 $252.00 (10%) | 🛒 Add to cart |
| 5 | $61.00 | $350.00 $305.00 (13%) | 🛒 Add to cart |
| 6 | $60.00 | $420.00 $360.00 (14%) | 🛒 Add to cart |
| 7 | $58.00 | $490.00 $406.00 (17%) | 🛒 Add to cart |
| 8 | $56.25 | $560.00 $450.00 (20%) | 🛒 Add to cart |
| 9 | $55.56 | $630.00 $500.00 (21%) | 🛒 Add to cart |
| 10 | $55.00
Best per injection | $700.00 $550.00 (21%) | 🛒 Add to cart |
Hucog HP is a highly purified human chorionic gonadotropin (hCG) formulation designed for medical use in fertility treatment and hormonal regulation. Manufactured under stringent quality controls, it offers reliable biological activity with minimal impurities, making it a trusted choice among reproductive endocrinologists and specialists. Its high purity profile supports predictable pharmacokinetics, aiding in tailored therapeutic protocols for patients requiring precise hormonal stimulation or supplementation.
Features
- Contains highly purified human chorionic gonadotropin (hCG)
- Available in multiple strengths (e.g., 1000 IU, 2000 IU, 5000 IU, 10000 IU per vial)
- Lyophilized powder formulation for enhanced stability
- Reconstitutes easily with provided bacteriostatic water
- Produced using recombinant DNA technology or urinary extraction under GMP conditions
- Low endotoxin levels compliant with pharmacopeial standards
- Precisely calibrated international units (IU) for dosing accuracy
Benefits
- Supports successful ovulation induction in anovulatory women when used as part of controlled ovarian stimulation protocols
- Triggers final follicular maturation and luteinization, optimizing timing for oocyte retrieval or timed intercourse
- Promotes testosterone production in hypogonadotropic hypogonadism in males, supporting spermatogenesis and secondary sexual characteristics
- Provides a reliable luteal phase support mechanism post-ovulation
- Enables customized dosing regimens due to product strength variety and predictable serum half-life
- Reduces risk of impurities-related adverse reactions compared to less purified formulations
Common use
Hucog HP is primarily indicated for the treatment of infertility in both women and men. In women, it is used to induce ovulation in those with ovulatory dysfunction, often following pretreatment with follicle-stimulating hormone (FSH). It is also central to assisted reproductive technology (ART) cycles, such as in vitro fertilization (IVF), where it is administered to trigger final oocyte maturation. In men, it is used to stimulate testosterone production in cases of hypogonadotropic hypogonadism, which can support the initiation of puberty or treat certain forms of infertility.
Dosage and direction
Dosage must be individualized under medical supervision based on diagnosis, treatment protocol, and patient response.
For ovulation induction in women:
A common dose is 5,000–10,000 IU administered as a single intramuscular (IM) or subcutaneous (SC) injection one day following the last dose of menotropins or other follicle-stimulating agents.
For controlled ovarian hyperstimulation in ART cycles:
Typically 5,000–10,000 IU IM or SC, or 250 mcg recombinant hCG if specified, when follicular maturation is deemed adequate via ultrasound and estradiol levels.
For male hypogonadotropic hypogonadism:
500–4,000 IU administered IM or SC 2–3 times per week for a duration specified by the treating physician. Dosage is titrated based on testosterone response.
Reconstitution:
Use only the provided diluent. Gently swirl (do not shake) the vial until the powder is fully dissolved. Administer promptly after reconstitution.
Precautions
- Use under strict medical supervision; self-administration should only occur after thorough patient education.
- Monitor for ovarian hyperstimulation syndrome (OHSS) in women—symptoms include abdominal pain, distension, nausea, vomiting, and weight gain.
- In men: monitor for excessive androgen response (e.g., acne, fluid retention, gynecomastia).
- Use with caution in patients with asthma, epilepsy, migraine, or renal or cardiac impairment.
- May affect thyroid function tests due to structural homology with TSH; interpret thyroid tests with caution during treatment.
- Not recommended for use in patients with hormone-dependent malignancies.
Contraindications
- Hypersensitivity to hCG or any component of the formulation.
- Prior allergic reaction to any gonadotropin product.
- Primary ovarian failure (as indicated by high FSH levels).
- Uncontrolled thyroid or adrenal dysfunction.
- Pituitary gland or hypothalamic tumors, except in certain approved fertility protocols.
- Abnormal uterine bleeding of undetermined origin.
- Ovarian cyst or enlargement not due to polycystic ovary syndrome (PCOS).
- Prostate cancer or other androgen-dependent neoplasms in males.
Possible side effect
Common:
- Headache
- Irritability
- Restlessness
- Fatigue
- Injection site reactions (pain, redness, swelling)
- Mild abdominal discomfort or bloating
Less common but significant:
- Ovarian hyperstimulation syndrome (OHSS)
- Ovarian torsion
- Adnexal torsion
- Thromboembolic events
- Gynecomastia in males
- Precocious puberty in young males
- Edema
- Depression
Drug interaction
- Concomitant use with other gonadotropins (e.g., FSH, LH) may enhance follicular growth and increase OHSS risk.
- Glucocorticoids may potentiate ovarian response.
- Testosterone or other androgens may interfere with treatment efficacy in males.
- Drugs affecting hormonal balance (e.g., aromatase inhibitors, clomiphene) may require dosage adjustments.
- Inform the prescriber of all current medications, including over-the-counter and herbal products.
Missed dose
If a dose is missed, contact the prescribing physician or fertility specialist immediately. Do not double the next dose to make up for a missed one. Timing is critical, especially in ovulation induction or ART cycles, where a missed hCG injection can compromise cycle success.
Overdose
Overdose may lead to severe OHSS in women, characterized by rapid weight gain, severe abdominal pain, vomiting, dyspnea, oliguria, and ascites. In men, overdose may cause excessive androgen effects such as aggressive behavior, extreme fluid retention, or priapism. There is no specific antidote; treatment is supportive and symptomatic. In cases of suspected overdose, seek immediate medical attention.
Storage
- Store unopened vials at 2–8°C (36–46°F); do not freeze.
- Protect from light.
- After reconstitution, use immediately or store as directed by the manufacturer (typically at 2–8°C for up to 30 days—confirm with product-specific literature).
- Keep out of reach of children and pets.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Hucog HP is a prescription medication and should be used only under the guidance of a qualified healthcare professional. Always follow the specific instructions provided by the prescribing physician and the product labeling. The author and publisher are not responsible for any misuse or adverse outcomes resulting from the use of this information.
Reviews
Clinical and patient feedback often highlights the consistency and reliability of Hucog HP in achieving therapeutic outcomes. Specialists appreciate its high purity, which correlates with predictable patient response and a favorable safety profile when used appropriately. Patients report satisfaction with clear instructions for reconstitution and administration, though individual experiences with side effects vary. Always consult with a healthcare provider to determine if this product is appropriate for your specific medical condition.